by Richard Cruse | Jan 19, 2021 | News
A year on from my last analysis of the World Federation for Hemophilia (WFH) Report on the Annual Survey we see in 2019 a further improvement in the number of people treated. However, we also see new data on the prevalence of the haemophilia A which suggests there are...
by Richard Cruse | Jul 15, 2020 | News
ProFactor Pharma Ltd (PFP), has completed an important development milestone in its programme to transform the treatment of ‘Haemophilia A’. The company has now received the second tranche of funding from its £2m funding round announced in September 2019 to advance...
by Richard Cruse | Jan 26, 2020 | News
We have been analysing the data provided by the World Federation for Hemophilia (WFH) for a number of years to develop our understanding of the market. Its Reports on the Annual Survey give details of the number of patients by country and the quantity of FVIII used....
by Richard Cruse | Nov 15, 2019 | News
Profactor Pharma Ltd is pleased to announce the appointment of Dr V Paul Gerskowitch to its board. Dr Gerskowitch joins the board of Profactor Pharma Ltd as an Investor Director with extensive, board level experience in the life sciences industries. He currently...
by Richard Cruse | Oct 30, 2019 | News
ProFactor Pharma Ltd (PFP) is set to transform the treatment of ‘Haemophilia A’ following the completion of its latest funding round. PFP has secured new investment of £2m in a funding round lead by the investment syndicate Kelvin Capital and supported by Ingenza Ltd...
by Richard Cruse | Dec 16, 2015 | News
Hope for Haemophiliacs Despite the controversy and disappointment emerging from the final report of the Penrose Inquiry into contaminated blood, which led to infection and death of hundreds of Scots, including haemophiliacs, new hope is emerging in a small laboratory...